Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1961 3
1965 1
1967 2
1968 5
1969 2
1970 5
1971 6
1972 5
1973 3
1974 3
1975 7
1976 3
1977 3
1978 3
1979 5
1980 1
1981 4
1982 2
1983 3
1984 2
1985 5
1986 5
1987 3
1988 2
1989 8
1990 7
1991 9
1992 4
1993 2
1994 2
1995 1
1996 9
1997 7
1998 4
1999 6
2000 3
2001 13
2002 7
2003 7
2004 8
2005 14
2006 12
2007 17
2008 10
2009 14
2010 12
2011 15
2012 20
2013 24
2014 27
2015 19
2016 19
2017 14
2018 12
2019 11
2020 19
2021 25
2022 33
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D. Harbeck N, et al. Among authors: bartsch r. Breast Care (Basel). 2024 Feb;19(1):1-9. doi: 10.1159/000533657. Epub 2023 Oct 5. Breast Care (Basel). 2024. PMID: 38384488
Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R, Jerzak KJ, Larrouquere L, Müller V, Le Rhun E. Bartsch R, et al. Cancer Treat Rev. 2024 Jan;122:102653. doi: 10.1016/j.ctrv.2023.102653. Epub 2023 Nov 7. Cancer Treat Rev. 2024. PMID: 38118373 Free article. Review.
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Lambertini M, et al. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. JAMA. 2024. PMID: 38059899
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.
Marhold M, Udovica S, Halstead A, Hirdler M, Ferner M, Wimmer K, Bago-Horvath Z, Exner R, Fitzal F, Strasser-Weippl K, Robinson T, Bartsch R. Marhold M, et al. Among authors: bartsch r. Oncoimmunology. 2023 Nov 13;12(1):2275846. doi: 10.1080/2162402X.2023.2275846. eCollection 2023. Oncoimmunology. 2023. PMID: 38025838 Free PMC article.
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.
Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, Exner R, Filipits M, Bago-Horvath Z, Rudas M, Bartsch R, Gnant M, Singer CF, Balic M, Egle D, Oehler R, Fitzal F. Wimmer K, et al. Among authors: bartsch r. J Exp Clin Cancer Res. 2023 Nov 14;42(1):300. doi: 10.1186/s13046-023-02876-x. J Exp Clin Cancer Res. 2023. PMID: 37957750 Free PMC article. Clinical Trial.
492 results